← Eichor
Study identifier: NCT06720272 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

School-based Program for the Prevention of Rheumatic Heart Disease in Endemic Regions

Condition: Rheumatic Heart Disease in Children  ·  Sponsor: Thomas Pilgrim

PhaseNA
Planned participants6000
Who can joinAll sexes, 5 Years to 16 Years
Healthy volunteersYes

About this study

The overall objective of the PREVENT trial is to evaluate the effectiveness of an integrated, school-based program for the prevention of rheumatic heart disease (RHD) in regions with an endemic pattern of RHD. We conduct a stepped wedge cluster randomized trial in randomly selected schools in Nepal and Zambia. The intervention will be delivered at the level of the school and consists in the introduction of a dedicated school-nurse program providing health care through education about RHD, assessment, intervention, and follow-up of GABHS pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with RHD.

This description comes directly from the study's public registry record.

Talk to the study team

Thomas Pilgrim Bern University Hospital, Bern, Switzerland  ·  +41 31 632 08 27  ·  thomas.pilgrim@insel.ch

Always discuss trial participation with your own doctor first.

Locations (2)

National Academy od Medical SciencesKathmandu, NepalRecruiting
Centre of Infectious Disease ResearchLusaka, ZambiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06720272